FDA approves Sanofi's Dupixent?

Analysis

Look, I'm skeptical of pharma hype as much as anyone, but this one's hard to argue against. Dupixent has sailed through ten FDA approvals already, and Sanofi knows exactly how to package these applications. The phase 3 data for chronic urticaria in kids was clean, and Europe greenlit it two weeks ago — which historically means the FDA isn't far behind. This isn't some moonshot experimental therapy. It's a supplemental application for a blockbuster drug with an established safety profile in pediatric populations. The regulatory playbook here is well-worn. Yes, the timeline is tight — only four days until the PDUFA date. And yes, one model flagged this as a reason to doubt. But here's the thing: the FDA set that date for a reason, and they typically hit their marks on straightforward supplemental applications like this. No advisory committee drama, no safety red flags, just bureaucratic box-checking. The science backs it, the track record backs it, and the European approval backs it. I'd bet on YES here — Dupixent's winning streak isn't ending on a routine label expansion.